Erlotinib Accord: Withdrawal of the marketing authorisation application



Accord Healthcare S.L.U. withdrew its application for a marketing authorisation of Erlotinib Accord for the treatment of non-small-cell lung cancer and pancreatic cancer.

The company withdrew the application on 11 May 2020.

Key facts

Erlotinib Accord
Product number
International non-proprietary name (INN) or common name
  • erlotinib
Date of withdrawal
Company making the application
Accord Healthcare S.L.U.
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating